Skip to main content


Log in

Efficacy and Safety of Long-Term Use of Dienogest in Women With Ovarian Endometrioma

  • Original Article
  • Published:
Reproductive Sciences Aims and scope Submit manuscript


Dienogest (DNG) is a progestin with highly selective progesterone activity and minimal androgenic activity and is helpful in reducing endometriosis-related pain. This study assessed the long-term efficacy and safety and recurrence rate of endometrioma with DNG use beyond 12 months of treatment. A retrospective cohort study was conducted with data collected from 7 university-affiliated hospitals and included a total of 514 women with ovarian endometrioma. All patients received 2 mg of oral DNG daily for at least 48 weeks postoperatively. During continuation of DNG, the recurrence rate of ovarian endometrioma on ultrasound, adverse events, changes in menstrual pattern, and pain score (visual analogue scale) were analyzed. The average period of DNG administration in this study was 72.2 + 5.2 weeks (range: 48-164). The recurrence rate of endometrioma was 1.8% (9 of 514), and the median duration to recurrence was 58 weeks (range: 24-76). Pain was described as overall improved by 82.2% of patients; 61.6% stated the pain was “improved” and 20.6% reported “much improved.” The mean VAS score was 4.9 at baseline and significantly decreased to 2.68, 2.2, 1.6, and 2.6 at 12, 24, 48, and 96 weeks. Amenorrhea rate was 58.3% in the first 12 weeks and increased to 86.4% at 72 weeks. Prolonged daily administration of 2 mg DNG followed by surgery was associated with a lower recurrence rate of ovarian endometrioma and a reduced pain score and symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others


  1. Giudice LC, Kao LC. Endometriosis. Lancet. 2004;364(9447):1789–1799.

    PubMed  Google Scholar 

  2. Ferrero S, Esposito F, Abbamonte LH, Anserini P, Remorgida V, Ragni N. Quality of sex life in women with endometriosis and deep dyspareunia. Fertil Steril. 2005;83(3):573–579.

    Article  PubMed  Google Scholar 

  3. Fourquet J, Gao X, Zavala D, et al. Patients’ report on how endo-metriosis affects health, work, and daily life. Fertil Steril. 2010;93(7):2424–2428.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kohler G, Goretzlehner G, Rudolf K, et al. The effect of a single midcycle administration of 0.5 or 2.0 mg dienogest (17 alpha-cyanomethyl-17 beta-hydroxy-estra-4,9-dien-3-one) on pituitary and ovarian function-investigation for the use as a postcoital contraceptive. Exp Clin Endocrinol. 1984;84(3):299–304.

    CAS  PubMed  Google Scholar 

  5. Jeng CJ, Chuang L, Shen J. A comparison of progestogens or oral contraceptives and gonadotropin-releasing hormone agonists for the treatment of endometriosis: a systematic review. Expert Opin Pharmacother. 2014;15(1):767–773.

    Article  CAS  PubMed  Google Scholar 

  6. Grandi G, Mueller M, Bersinger N, et al. Progestin suppressed inflammation and cell viability of tumor necrosis factor-alpha-stimulated endometriotic stromal cells. Am J Reprod Immunol. 2016;76(4):292–298.

    Article  CAS  PubMed  Google Scholar 

  7. Bizzarri N, Remorgida V, Leone Roberti Maggiore U, et al. Die-nogest in the treatment of endometriosis. Expert Opin Pharmac-other. 2014;15(13):1889–1902.

    Article  CAS  Google Scholar 

  8. Spona J, Feichtinger W, Kindermann C, et al. A 19-norprogestin without a 17alfa-ethinyl group II: dienogest from a pharmady-namic point of view. Drugs Today. 1995;31(7):517–536.

    Google Scholar 

  9. Sasagawa S, Shimizu Y, Kami H, et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacoki-netic profile. Steroids. 2008;73(2):222–231.

    Article  CAS  PubMed  Google Scholar 

  10. Harada T, Taniguchi F. Dienogest: a new therapeutic agent for the treatment of endometriosis. Womens Health. 2010;6(1):27–35.

    CAS  Google Scholar 

  11. Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2010:(12):Cd008475.

  12. Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Dieno-gest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010;25(3):633–641.

    Article  CAS  PubMed  Google Scholar 

  13. Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Detailed analysis of a randomized, multicenter, comparative trial of dieno-gest versus leuprolide acetate in endometriosis. Int J Gynaecol Obstet. 2012;117(3):228–233.

    Article  CAS  PubMed  Google Scholar 

  14. Harada T, Momoeda M, Taketani Y, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis-a randomized, double-blind, multicenter, controlled trial. Fertil Steril. 2009;91(3):675–681.

    Article  CAS  PubMed  Google Scholar 

  15. Park SY, Kim SH, Chae HD, Kim CH, Kang BM. Efficacy and safety of dienogest in patients with endometriosis: a single-center observational study over 12 months. Clin Exp Reprod Med. 2016;43(4):215–220.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Adachi K, Takahashi K, Nakamura K, et al. Postoperative administration of dienogest for suppressing recurrence of disease and relieving pain in subjects with ovarian endometriomas. Gynecol Endocrinol. 2016;32(8):646–649.

    Article  CAS  PubMed  Google Scholar 

  17. Takaesu Y, Nishi H, Kojima J, et al. Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis. J Obstet Gynaecol Res. 2016;42(9):1152–1158.

    Article  CAS  PubMed  Google Scholar 

  18. Cho S, Jung JA, Lee Y, et al. Postoperative levonorgestrel-releasing intrauterine system versus oral contraceptives after gonadotropin-releasing hormone agonist treatment for preventing endometrioma recurrence. Acta Obstet Gyn Scan. 2014;93(1):38–44.

    Article  CAS  Google Scholar 

  19. Lee DY, Bae DS, Yoon BK, Choi D. Post-operative cyclic oral contraceptive use after gonadotrophin-releasing hormone agonist treatment effectively prevents endometrioma recurrence. Hum Reprod. 2010;25(12):3050–3054.

    Article  CAS  PubMed  Google Scholar 

  20. Seracchioli R, Mabrouk M, Frasca C, Manuzzi L, Savelli L, Venturoli S. Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertil Steril. 2010;94(2):464–471.

    Article  PubMed  Google Scholar 

  21. Sugimoto K, Nagata C, Hayashi H, Yanagida S, Okamoto A. Use of dienogest over 53 weeks for the treatment of endometriosis. J Obstet Gynaecol Res. 2015;41(12):1921–1926.

    Article  PubMed  Google Scholar 

  22. Klipping C, Duijkers I, Remmers A, et al. Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmaco-dynamic trial of healthy women. J Clin Pharmacol. 2012;52(11):1704–1713.

    Article  CAS  PubMed  Google Scholar 

  23. Schindler AE, Christensen B, Henekel A, Oettel M, Moore C. High-dose pilot study with the novel progestogen dienogest in patients with endometriosis. Gynecol Endocrinol. 2006;22(1):9–17.

    Article  CAS  PubMed  Google Scholar 

  24. Mori T, Ito F, Matsushima H, et al. Dienogest reduces HSD17 beta 1 expression and activity in endometriosis. J Endocrinol. 2015;225(2):69–76.

    Article  CAS  PubMed  Google Scholar 

  25. Choi J, Jo M, Lee E, Lee DY, Choi D. Dienogest enhances autop-hagy induction in endometriotic cells by impairing activation of AKT, ERK1/2, and mTOR. Fertil Steril. 2015;104(3):665–664.

    Article  Google Scholar 

  26. Kim SA, Um MJ, Kim HK, Kim SJ, Moon SJ, Jung H. Study of dienogest for dysmenorrhea and pelvic pain associated with endo-metriosis. Obstet Gynecol Sci. 2016;59(6):506–511.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Grandi G, Xholli A, Napolitano A, Palma F, Cagnacci A. Pelvic pain and quality of life of women with endometriosis during quadriphasic estradiol valerate/dienogest oral contraceptive: a patient-preference prospective 24-week pilot study. Reprod Sci. 2015;22(5):626–632.

    Article  CAS  PubMed  Google Scholar 

  28. Strowitzki T, Faustmann T, Gerlinger C, Seitz C. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol. 2010;151(2):193–198.

    Article  CAS  PubMed  Google Scholar 

  29. Petraglia F, Hornung D, Seitz C, et al. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch Gynecol Obstet. 2012;285(1):167–173.

    Article  PubMed  Google Scholar 

  30. Momoeda M, Harada T, Terakawa N, et al. Long-term use of dienogest for the treatment of endometriosis. J Obstet Gynaecol Res. 2009;35(6):1069–1076.

    Article  CAS  PubMed  Google Scholar 

  31. Gerlinger C, Faustmann T, Hassall JJ, Seitz C. Treatment of endometriosis in different ethnic populations: a meta-analysis of two clinical trials. BMC Womens Health. 2012;12:9.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Finkelstein JS, Lee MLT, Sowers M, et al. Ethnic variation in bone density in premenopausal and early perimenopausal women: Effects of anthropometric and lifestyle factors. J Clin Endocr Metab. 2002;87(7):3057–3067.

    Article  CAS  PubMed  Google Scholar 

  33. Seeman E. Estrogen, androgen, and the pathogenesis of bone fragility in women and men. Curr Osteoporos Rep. 2004;2(3):90–96.

    Article  PubMed  Google Scholar 

  34. Popat VB, Calis KA, Vanderhoof VH, et al. Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab. 2009;94(7):2277–2283.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Guerriero S, Mais V, Ajossa S, et al. The role of endovaginal ultrasound in differentiating endometriomas from other ovarian cysts. Clin Exp Obstet Gynecol. 1995;22(1):20–22.

    CAS  PubMed  Google Scholar 

  36. Van Holsbeke C, Van Calster B, Guerriero S, et al. Endometriomas: their ultrasound characteristics. Ultrasound Obstet Gynecol. 2010;35(6):730–740.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding authors

Correspondence to Dong-Yun Lee MD, PhD or SiHyun Cho MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, S.R., Yi, K.W., Song, J.Y. et al. Efficacy and Safety of Long-Term Use of Dienogest in Women With Ovarian Endometrioma. Reprod. Sci. 25, 341–346 (2018).

Download citation

  • Published:

  • Issue Date:

  • DOI: